There are 410 resources available
Adjuvant TKI for 3 years or less
Presenter: Helena A. Yu
Session: Optimal duration of adjuvant TKI
Resources:
Slides
Webcast
Second vote and conclusions
Presenter: Silvia Novello
Session: Is there a place for conformal PORT in 2023?
Resources:
Slides
Webcast
Adjuvant TKI for more than 3 years
Presenter: Natasha Leighl
Session: Optimal duration of adjuvant TKI
Resources:
Slides
Webcast
143MO - Risk of lung cancer among current smokers by pack-year smoking: A cohort study with 23 years of follow-up
Presenter: Joel Nations
Session: Mini Oral 1
Resources:
Abstract
Invited Discussant 7MO, 8MO and 143MO
Presenter: Navneet Singh
Session: Mini Oral 1
Resources:
Slides
Webcast
Discussion
Presenter: Natasha Leighl
Session: Optimal duration of adjuvant TKI
Resources:
Webcast
9MO - Profile of immunorecognition related markers including HLA-1 expression to predict response to immunocheckpoint inhibitors in non-small cell lung cancer
Presenter: Maria Saigi Morgui
Session: Mini Oral 1
Resources:
Abstract
Slides
Webcast
145MO - Updated survival, efficacy and safety of adjuvant (adj) atezolizumab (atezo) after neoadjuvant (neoadj) atezo in the phase II LCMC3 study
Presenter: David Carbone
Session: Mini Oral 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 9MO and 145MO
Presenter: Fernando Lopez-Rios
Session: Mini Oral 1
Resources:
Slides
Webcast
84O - Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816
Presenter: Nicolas Girard
Session: Proffered Paper 2
Resources:
Abstract
Slides
Webcast